Clinical Trials Logo

Clinical Trial Summary

Rapid eye movement (REM) sleep behavior disorder (RBD) is a sleep disorder in which you act out dreams during REM sleep. Sleep disturbances are very common in RBD, where they negatively impact patients' quality of life and safety. One of the known causes of sleep disturbance is the impairment of the "circadian rhythm", or the human sleep/wake cycle. The purpose of this study is to examine the role of disruption of the circadian rhythm in the development of RBD.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04886076
Study type Observational
Source Massachusetts General Hospital
Contact Aleksandar Videnovic, M.D.
Phone (617) 724-3837
Email avidenovic@mgh.harvard.edu
Status Recruiting
Phase
Start date December 7, 2018
Completion date December 2021

See also
  Status Clinical Trial Phase
Recruiting NCT04534023 - A Clinical Study of the Efficacy of Idebenone in the Treatment of iRBD Into Synucleinopathies Phase 2
Terminated NCT05307770 - Extended-Release Melatonin in Patients With Rapid Eye Movement Sleep Behavior Disorder N/A
Active, not recruiting NCT00817726 - RBD Longitudinal as Prognostic for PD
Active, not recruiting NCT04020198 - A Pilot Biomarker Study Assessing Alpha-synuclein Aggregates Across Biofluid Reservoirs in Patients With Synucleinopathies